A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-20 and is reviewed periodically as new material appears.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
On 10 January 1945, Stalin called Yugoslavia's foreign policy unreasonable because of its territorial claims against most of its neighbours, The USSR and Yugoslavia signed a friendship treaty when Tito met with Stalin in Moscow in April 1945.
=== Sézary cells === Sézary cells are bigger than Lutzner cells, and have an overabundance of cellular folds in the membrane. They are also considered over pigmented and have large cerebriform nuclei with a small cytoplasm. Sézary cells are found in both mycosis fungoides and Sézary disease.
== Adverse reactions == The common, adverse drug reactions (side effects) are the same as with other PDE5 inhibitors. The frequent vardenafil-specific side-effect is nausea; the infrequent side effects are abdominal pain, back pain, photosensitivity, abnormal vision, eye pain, facial edema, hypotension, palpitation, tachycardia, arthralgia, myalgia, rash, itch, and priapism. One possibly serious, but rare, side effect with vardenafil is heart attack. Also, in rare cases, vardenafil use may cause priapism, a very painful emergency condition that can cause impotence if left untreated. In October 2007, the U.S. Food and Drug Administration (FDA) announced that a warning about possible deafness (sudden hearing loss) would be added to the drug labels of vardenafil, and other PDE5 inhibitors.
==== United States ==== The U.S. Food and Drug Administration (FDA) is the agency responsible for regulation of radiation sources in the United States. Irradiation, as defined by the FDA is a "food additive" as opposed to a food process and therefore falls under the food additive regulations. Each food approved for irradiation has specific guidelines in terms of minimum and maximum dosage as determined safe by the FDA. Packaging materials containing the food processed by irradiation must also undergo approval. The United States Department of Agriculture (USDA) amends these rules for use with meat, poultry, and fresh fruit. The United States Department of Agriculture (USDA) has approved the use of low-level irradiation as an alternative treatment to pesticides for fruits and vegetables that are considered hosts to a number of insect pests, including fruit flies and seed weevils. Under bilateral agreements that allows less-developed countries to earn income through food exports agreements are made to allow them to irradiate fruits and vegetables at low doses to kill insects, so that the food can avoid quarantine. The U.S. Food and Drug Administration and the U.S. Department of Agriculture have approved irradiation of the following foods and purposes:
Sources: en.wikipedia.org
For example, changes in farming practices such as the indoor raising of cattle and incineration or burial of cattle carcasses have reduced food availability for Eurasian griffon vultures. Shootings of birds, removal of nestlings from nests, and drug pollution have also contributed to declines in vulture populations.
Approximately two billion years ago, a free-living cyanobacterium entered an early eukaryotic cell, either as food or as an internal parasite, but managed to escape the phagocytic vacuole it was contained in and persist inside the cell. This event is called endosymbiosis, or "cell living inside another cell with a mutual benefit for both". The external cell is commonly referred to as the host while the internal cell is called the endosymbiont. The engulfed cyanobacteria provided an advantage to the host by providing sugar from photosynthesis. Over time, the cyanobacterium was assimilated, and many of its genes were lost or transferred to the nucleus of the host. Some of the cyanobacterial proteins were then synthesized by the host cell and imported back into the chloroplast (formerly the cyanobacterium), allowing the host to control the chloroplast. Chloroplasts which can be traced back directly to a cyanobacterial ancestor (i.e. without a subsequent endosymbiotic event) are known as primary plastids ("plastid" in this context means almost the same thing as chloroplast). Chloroplasts that can be traced back to another photosynthetic eukaryotic endosymbiont are called secondary plastids or tertiary plastids (discussed below). Whether primary chloroplasts came from a single endosymbiotic event or multiple independent engulfments across various eukaryotic lineages was long debated.
== Second ministry == On 29 May 1969, following the 1969 election on 17 May, the Ministry was reconstituted by the Administrator, William Mack, due to the Governor's absence, and served until the next reconstitution of the ministry on 20 June 1972. There were almost no changes—Harold Richter retired from politics, and Nev Hewitt was appointed to the resulting cabinet vacancy. On 4 September 1969, the cabinet was expanded from 13 to 14 members, and Wally Rae was appointed. On 19 December 1971, Peter Delamothe, the Attorney-General and Minister for Justice, resigned to take up an appointment as Agent-General of Queensland. His position in the ministry was left vacant for the remainder of the term, while William Knox was appointed to his former roles.
=== Houston Astros === Bagwell spent his entire major-league career with the Houston Astros. Alongside teammate Craig Biggio, he was associated with the group of Astros players known as the “Killer B’s” during the 1990s and 2000s. From 1994 to 2003, Bagwell and Biggio combined for nine All-Star selections, five Gold Glove Awards, five top-five finishes in Most Valuable Player voting, 689 home runs, 2,485 runs batted in and 3,083 runs scored. During this period, the Astros reached the postseason six times. With an exaggerated and unusual batting style, Bagwell waited for each pitch in a low crouch, with legs wide open and knees bent nearly 90 degrees, appearing as if he was sitting on an invisible bench. He stepped back with his front foot as he began his swing. Next, he would rise from his stance and rotate his hands with the bat forward into his powerful, uppercut swing. "That wide stance keeps him from over striding", Joe Torre observed, "which can be your biggest problem when you're trying to hit for power." The low crouch also shrunk his strike zone, allowing him to walk more often. Standing 6 feet tall (72 inches (180 cm)) and weighing 195 pounds (88 kg), he did not present the image of an imposing, home run-hitting giant that would cause pitchers to be very careful when he batted after he began his major league career.
She has been affiliated with Brigham and Women's Hospital and is a member of the intramural faculty at the Koch Institute for Integrative Cancer Research. She served on the National Cancer Institute (NCI) Board of Scientific Advisors and co-led the first synthetic biomarker think tank at the NCI (SYNDICATE) with the late Sanjiv Gambhir. She also co-chaired the first AACR conference on Precision Prevention, Early Detection, and Interception of Cancer, and the annual Irwin M. Arias Symposium, a leading event in liver research.
Sources: en.wikipedia.org
== Overview == Thyrotropic cells (also called thyrotropes, or thyrotrophs) are endocrine cells in the anterior pituitary which produce thyroid-stimulating hormone (TSH) in response to thyrotropin-releasing hormone (TRH) from the hypothalamus. Thyroid-stimulating hormone, or thyrotropin, triggers the release of thyroxine (T4) and triiodothyronine (T3) from the thyroid gland. Thyrotropes comprise around 5% of the anterior pituitary lobe cells.
Prior to its independence, the government of the Federation of Malaya was headed by a British high commissioner with executive powers, assisted and advised by the Federation of Malaya Executive Council and the Federation of Malaya Legislative Council.
== Career and writing == After leaving Oxford, Halliwell briefly lectured at the Portsmouth Polytechnic (1973–74). He took up a position as lecturer at King's College London in 1974, remaining there until 2000, rising to the position of Professor of Medical Biochemistry in the Division of Pharmacology. He also simultaneously held a visiting professorship at the University of California, Davis, United States (1995–99). After a 1998 sabbatical at the National University of Singapore (NUS), he moved there in 2000 as chair of the biochemistry department. As of 2018 he is a professor in the department of biochemistry at the NUS Yong Loo Lin School of Medicine. Halliwell is currently the Senior Advisor, Academic Appointments and Research Excellence, Office of the Provost, at the National University of Singapore (NUS). He is also Chairman of the Biomedical Research Advisory Council (BMAC), Agency for Science, Technology & Research (A*STAR). Halliwell served as the NUS's first Deputy President (Research and Technology) in 2006–15, founding the Graduate School for Integrative Sciences and Engineering, and overseeing a more than doubling in the university's research grants and the creation at NUS of Singapore's first Research Centre of Excellence (RCEs). He was subsequently appointed Senior Advisor to the NUS President. His textbook, Free Radicals in Biology and Medicine, co-written with John M. C. Gutteridge, is considered "an authoritative text in the field".
== RNA == RNA is subdivided into many categories, including messenger RNA (mRNA), ribosomal RNA (rRNA), transfer RNA (tRNA), long non-coding RNA (lncRNA), and several other small functional RNAs. Whereas many proteins have quaternary structure, the majority of RNA molecules have only primary through tertiary structure and function as individual molecules rather than as multi-subunit structures. Some types of RNA show clear quaternary structure that is essential for function, whereas other types of RNA function as single molecules and do not associate with other molecules to form quaternary structures. Symmetrical complexes of RNA molecules are extremely uncommon compared to protein oligomers. One example of an RNA homodimer is the VS ribozyme from Neurospora, with its two active sites consisting of nucleotides from both monomers. The best known example of RNA forming quaternary structures with proteins is the ribosome, which consists of multiple rRNAs, supported by rProteins. Similar RNA-Protein complexes are also found in the spliceosome.
Picamilon (also known as N-nicotinoyl-GABA, pycamilon, and pikamilon) is a drug formed by a synthetic combination of niacin and γ-aminobutyric acid (GABA). It was developed in the Soviet Union in 1969 and further studied in both Russia and Japan as a prodrug of GABA. In Russia, picamilon is sold as a prescription drug. The rights to the drug belong to the Russian pharmaceutical company NPK ECHO ("НПК ЭХО"). It is not approved for sale in the United States and has been deemed an adulterating agent in dietary supplements, with five American companies required to remove their picamilon products from the market in November 2015. However, as recently as 2020, picamilon has been found in pharmaceutical dosages in over-the-counter supplements in the US.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.